Video: Recovered Recording Updated Biocompatibility And Biological Safety Of Medical Devices | Duration: 2650s | Summary: Recovered Recording Updated Biocompatibility And Biological Safety Of Medical Devices | Chapters: Conclusion and Takeaways (0s)
Transcript for "Recovered Recording Updated Biocompatibility And Biological Safety Of Medical Devices": Welcome and hello to our... Today's keynote on biocompatibility and biological safety of medical devices. My name is Sylvia Georges. And before we start, I first like to introduce myself a bit to you. I'm a biologist by education, and I did my PhD in, neuroscience in the beautiful city of Tubingen in the South Of Germany at the Max Planck Institute. Excuse me. And, during this PhD, I had the opportunity being an animal f... Animal welfare officer at the Max Planck Institute, and these were my first experience with regulatory affairs in the German animal welfare law. Right? After I finished my PhD, I took a brief step into the pharma industry. I was a medical manager in, here, allergeology and emergency medicine, and I did an education in, clinical research as as a clinical research associate before I started at NSF in 2018 already and entered the big colorful world of medical devices back then. I started on clinical evaluations. There was, the transition from MDD to MDR back then. It was really exciting. Before in 2019, we started to develop the service of biological evaluations here at NSF in Hamburg. And now we provide our service according to ten nine three, but also 2362. This is all done in our clinical affairs team. It's a team of around 20 well educated natural scientists mostly, mostly having a PhD, and they take care of the research questions in medical devices. Right? This is one of our team for which I am the manager along with my colleague, and we have, another team focusing on regulatory affairs and on quality management system. So, yeah, quality management. What we also do beyond clinical evaluation and biological safety is clinical studies, of course. I myself personally focus on biostatistics, you know, sample size estimations, data analysis, something like this, and performance evaluations regarding the IVD. And I take advice from my colleagues from the other teams, if I need regulatory advice in IVD. So you see we have different divisions, different experts, and very qualified people here, and we work as a team, sharing our advice with with you, basically, with our clients, with our colleagues, with our, yeah, peers in the field. Let's talk a little bit about NSF. NSF is a global company with the mission to improve and protect human and planet health. It's more than 80 years old. So a couple of years, we we celebrated eighty years. Yeah. It's globally, and we, yeah, we follow this dedication in three core industries. There's food and nutrition, there's water, and there's life sciences. And we, with medical devices and, pharma, we are located in the life science division of NSF. And within life science, we, yeah, we are distributed all over the world, so you can consult locally. Basically, we act globally, so we also have experience in different regulations in different countries. This is really an advantage, and our services focus on auditing, consulting, which includes documentation. So from the medical device. So in the medical device field, we do classically all, related to technical documentation. In pharma, it's, of course, all in pharma, like investigator brochures, CTDs, something like this. And we also provide training and workshop in all the relevant areas in life science. So even, tailored to your need. Product specifically, the medical device world is really colorful. Every product is different and follow different... Not different regulations, but different strategies. Right? And we provide tailored product specific training and workshops. Our solution areas are pharma and biotech combination products, of course. It combines pharma and medical devices within one product. Of course, medical devices and also IVTs. At NSF here in Hamburg, we, yeah, we focus on medical devices since 1999. So this company developed from NSF ProSystem, so it was formerly ProSystem. And ProSystem is in Hamburg since 1999, and we are now with NSF. So we have more than twenty six years now, almost twenty seven years experience in medical devices and following the entire life cycle of a medical device. So from the first idea, biologically speaking, from the first material, to the disposal of a medical device, we cover every challenge, every question along the life cycle. All our services are certified according to ISO thirteen four eighty five, which brings advantages in relation to supplier audits, for example. This is really, yeah, helpful. Yeah. Enough of me, NSF, and our medical device world. Ah, I forgot something about, NSF in Hamburg. So since recently... So we focus on medical devices since twenty seven years. But since recently, since the beginning of this year, we recruited or we are working... We're not... We did not recruit. We are working together with our colleagues in UK and in America developing the service for the pharma industry here at NSF in Hamburg. So we... In the future, we cover pharma and medical devices. And so, yeah, our clients can get everything from one basket. Right? It's sometimes... So especially in case of combination products, we can cover everything from one basket, and this is sometimes really advantageous. I skipped the agenda. Coming to today's agenda after my introduction and our company, the agenda for today, talking about biological evaluation of medical devices, is first, I would like to do a recap on the key changes of the new revision of ISO ten ninety three dash one. It was published in November 2025. You can see it here on the right side, and there were big changes. It was really a big revision. I just take a brief recap here, but if you want to know more or have more details on the changes in comparison to the previous revision from, 2018, just check our keynote. It's available on demand, which I did in February. And there you can get, in a nutshell, in forty five minutes all the changes and what they might, yeah, mean in the future. Well, it's now. Right? That's what I want to talk about in the second point of my agenda. One year in, it's not a complete year. It was published in November, so it's eleven months, something like this, almost a year. And I would like to share our experience from our team, which we gathered in the last year along with our clients, with notified body, with discussion, with peers, with other consultants, manufacturers, but also from conferences, right, where we discussed with other people sharing the challenge of getting into this new revision of ten nine nine three dash one. And finally, one of the major discussions, discussions which we had in the last year is about the FDA expectations for biological evaluation. And there, I want to give you an insight and share some of the experience with you. Starting with the key changes. So what was changed? The first and most prominent change was the greater alignment with the risk management framework, although it was not really a change. The biological evaluation was always intended to be conducted within a risk management process. However, it was in the past not very well understood how this should be done in practice. Right? The question was, how are the process steps or the tasks within ISO ten nine nine three related to the risk management process described in ISO fourteen nine seventy one? And the beauty in the new revision is that you can see it on the slide. If you were in my keynote in February, you remember the slide. On the left side, we have a flowchart which was copied from ISO fourteen nine seventy one. And in color code, I indicated the process steps in ISO ten nine nine three dash one. And it's it's, yeah, summarized in one flowchart. And this is really easy to follow, and there's guidance text below and above, and it's now really clearly outlined how this process should work, and it's now enabled to follow this process in in practice. Right? Along with the alignment of the risk management framework came the risk based approach. So not... It was also previously acknowledged and conducted, but it was also not very well understood how to follow it. But it's really advantageous, and we use it on a regular day... On daily basis basically. The principle is that you... So the more invasive the contact type of your medical device, which is here on the y axis, and the longer the contact duration of your medical device, the higher is the associated biological risk and the more rigorous and detailed your biological evaluation should be. This implies that the less acceptable are any data gaps. So if you have a limited device, for example, in contact with intact skin, it's a very well known or well established technology made from well known materials. You evaluate available data, have some data gaps, of course, but they are rather insignificant and acceptable and you are still able... Or the evaluators are still able to conduct the risk assessment according to forty nine seventy one. But the higher the associated biological risk is, the less acceptable are any data gaps. So you need to add up or support your available information with testing data. You can go over chemical characterization, analysis, get your chemical profile, extractable, switchable profile, or even, finally, if you have a long term device and or invasive contact duration, go with biological safety testing, maybe even animal testing. Right? Also related to the risk management framework was the introduction of, reasonably foreseeable misuse. This is still under discussion, which... So reasonably foreseeable misuse was also before in ISO forty nine seventy one, but not explicitly stated in ISO 10 s three. So this needs to be considered, and there is a lot of discussion going on, how detailed this reasonably foreseeable misuse should be, how it is considered in in the past, is it related to biological safety or not. It's not easy, but this was an introduction. Risk managers know about the challenge because it was always there for ISO forty nine seventy one. Yeah. But we hope there will be more guidance in the future. The second change, which had an impact, a huge impact, was the extended contact duration in specific cases. And these specific cases are, medical devices which are repeatedly used on one patient. And, for these, they introduced a contact day. So the definition of a contact day is a day in which a medical device or component thereof comes into contact irrespective of the length of time of that contact. So previously, with the 2018 revision of dash one, we summed up the contact duration. So if a medical device was used three times, each contact was four hours, it was summed up to twelve hours. Twelve hours was still less than limited, less than twenty four hours, and it was in the limited contact duration category. Right? Now it's three contacts, so it's automatically three days. And three days extends the limited contact duration and goes into the prolonged contact duration. This has an impact on the risk profile, the associated biological risk profile, because the longer the contact duration, the higher the associated risk. Right? Bioaccumulation was introduced. As soon as there is an indicator of bioaccumulation of one substance or one material in the medical device or as a residue on the medical device, it should be evaluated as being in long term contact. So even beyond thirty days, this was also introduced, aligned with the worst case strategy of ISO 10,993. The third change, was related to the table. So this huge comprehensive table a one disappeared. The one in which we categorize... Or which we used as a tool to categorize our medical device and then identify the hazards related to the related to the medical device named endpoints. They are now relaying to biological effects. And this table disappeared from the attachment. It's now in the main text and distributed or divided in four tables. You can still use it or you should still use it as, yeah, to identify the hazards and to categorize your device. The first one is for devices in contact with intact skin. The second one, intact mucosal membrane. The third one covers all the invasive contact types except for circulating blood, which is then in the fourth table. Yeah. And last but not least, there were some changes on the endpoints or the biological effects, yeah, which were renamed to biological effects. First, systemic toxicity is now introduced as a general category and the evaluation which, well, I would say which kind of systemic toxicity reflects the duration of use. So if you evaluate acute, subacute, subchronic, or chronic, it's on the evaluator and should be related to the duration of use. Implantation effects were renamed to local effects after tissue contact in favor of medical devices which are not implanted. For example, devices in contact... Prolonged contact with intact mucosal membrane. Surprisingly, the related ISO 10,003 dash six was published in the meantime since dash one was was revised or published in the end last year, still referring to local effects after implantation. So, actually, there is now at this date, a gap how to evaluate medical devices on this specific biological effect, local effects after tissue contact if it's not implanted. Last week, I was on a conference and I talked to to, yeah, a person who is in the technical committee who developed ISO 10,903 dash one, and he told me they had six projects ongoing still filling gaps in the standard, and this is one of them, unfortunately. Yeah. The second is, material mediated pyrogenicity. It was a big focus in the last revision of the standard. Now it disappeared from the focus, and it's still to be... It's only to be evaluated if there are constituents which have previously elicited a pyrogenic response, so which are known to have a pyrogenic response, or if the potential is completely unknown, if you have no idea for novel materials, for example. Otherwise, you follow state of the art and, the evaluation should be sufficient for pyro... Material mediated pyrogenicity. Evaluation of genotoxicity is more broadly required for all devices in prolonged contact except for contact with intact skin. In this relation, ISO ten nine nine three dash three was revised and published couple of weeks ago. It was only recently. And here, the update was really, yeah, it was really advantageous because before... So there was, a conventional strategy to conduct in vitro genotoxicity testing. And if this is positive, follow with in vivo genotoxicity toss... Testing in order to evaluate the biological or the toxicity... The genotoxicity potential of a material or a component. And now it changed to the chemical characterization toxicological risk assessment strategy, which is now aligned with, the general ten ninety three dash one strategy on other biological effects, which is also more reasonable to follow in relation to genotoxicity. Cardinogenicity should be evaluated if genotoxic constituents are present. And if they are not present, there is also non genotoxic mechanisms, but this only impact the patient's safety after long term exposure. So this is only required after long term exposure. Yeah. Those were the changes in a nutshell. Now I would like to share our experience from the last year within or working with this new revision of ten nine l three dash one. I have four kinds of insights. I start with practical insights. There are also economical insights, regulatory insights, and formal insights. So starting with the practical insights, we learned that, previously... This was also... Well, yeah, how it generally was previously done. The risk management and the biological evaluation was completely separated because the, yeah, the interface and the strategies, the process steps were just not clear as I introduced in the beginning showing this flowchart. Right? If at all there were interfaces by references, going from the BEP, the biological evaluation plan, to the risk management file, maybe also to the biological evaluation report, but there was no clear understanding, and risk management was majorly neglected in the past. But now with the with the new standard, we, as consultants, we do not have to provide entire trainings on the process steps. So it's clear from the description and clarifications within the standard, how the risk management file can be fully integrated with the biological evaluation and how a structured risk estimation and evaluation may be performed. So there's a better understanding of the process and also the risk based approach, which is, yeah, more frequently used than in the past, which I really like. However, there's still uncertainty about thresholding and acceptance criteria. So thresholding also in relation relation to risk estimation, how to either... Or determine probability of occurrence of harm and severity of that harm to conduct the risk estimation and how to determine acceptability criteria or acceptance criteria to conduct the risk evaluation. So this is still uncertain. There is a little bit more guidance needed on this one, but this is also coming. The questions are now less which testing is relevant and needs to be conducted. More into the direction of what are the actual risks and which related evidence is sufficient for the evaluation, referring to the risk based approach. So what is the detail and the rigor of my biological evaluation? And if I have a device in limited contact with intact skin, is this really a risk, or can I accept a data cap and still be able to do risk assessment? Because, actually, there is no risk. Yeah. This is really great coming to economical insights, which is also a special interest. On short term... Well, I got a few of these. We need to do all this stuff. But it's... Yeah. It's... We we went through this, and it went better than expected. There were some unplanned reevaluation of devices due to the introduction of the contact days because the requirements are if the contact duration is prolonged due to the contact days and the device shifts from a limited contact duration to prolonged, then there may be more unchanged endpoints if it's not in contact with IntexSCAN. Right? So this is associated with a higher risk potential, which requires more detail and more rigor. And the evaluation of these additional biological effects is time consuming, often expensive because you need to work on the available data. You need to acquire available data, talk to suppliers, get all this information, and, yeah, reevaluate this in, yeah, along with the existing biological evaluation. But in long term, there is less testing, but in-depth evaluation of available data in relation to design changes, for example. So what we already experienced now is that if manufacturers go into design changes and want to change a material or maybe an entire component, they acquire this material already with sufficient biological safety data coming with the material, be it medical grade already tested for ISO 10 o three dash five, 23 or 10 for cytotoxicity, irritation, sensitization, something like this in order to avoid future testing. So this is something which really worked out quite nicely. So in the end, I wouldn't say that there are more resources going into the risk based approach and using available data. It's just, yeah, going from the check mark approach, which... Where the resources went into the labs and testing, which was also time consuming, also very expensive, to the use of available data. Testing is included or... Yeah. Yeah. Still included into consideration for... Especially for higher risk devices, right, to fill data gaps, but it's less testing. You don't need the entire... Or we, as an evaluator, we don't need the entire test battery anymore, but only fill the gaps. The regulatory insights include... Well, the additions and also alignment with the risk management process. There is this foreseeable misuse I mentioned in the beginning that it's highly discussed, and it's a discussion for decades going on, in relation to ISO fourteen nine seventy one. How detailed these considerations of foreseeable misuse should be. So how... Well, I I were in brainstormings, and we made up really exotic scenarios, which would never happen. Right? And, yeah. And in addition to this, so how... Yeah. Where do I get the information and what is foreseeable misuse? How is this related to biological safety? A big help is a little word word in the ISO ten ninety three dash one. It states in one note, systematically misuse, foreseeable misuse. And this helps a lot, in in the thinking of if it happens systematically or if I can imagine that it happens repeatedly, then I consider it in my, biological evaluation. But, of course, we should also consider the risk based approach. The higher the risk, maybe the more thinking on foreseeable misuse, it's still... Yeah. There's always uncertainty about this foreseeable misuse, especially in relation to biological safety. So how is it related to biological safety? Sometimes it's related to usability. The distinguish... So how to distinguish this is sometimes not easy. And what kind of data can be used? Well, basically, all the data can be used as long as it's valid data. Yeah? Okay. There are higher expectations on the documentation. So the new revision of 1093 dash one was published. And a week later, we had a document or a a technical documentation with the notified body. And the response came back and it included, please include the gap analysis according to the new standard. So they reacted immediately. And, what we also experienced is that the review of BEP in alignment with the risk management file and also the BEPAR is more critical. Of course, because it's not align... Not... Yeah. Well, stream... It's not, stand... Yeah. Well, stand and I I don't know the right word for this. But before, many, many technical documentation went to the notified body with a cover page. The testing battery was done. Check mark approach was followed. All testings passed, and it went through. It was easy to follow. Right? Now there is a data compilation. Available data is combined with testing data. This is an iterative process. After each process steps, it goes into the risk assessment. Gaps are defined. Significance of that gaps are defined. Necessity necessity of testing is, justified. And there are even justifications, recommended in the standard or rather there are examples in the standards how... Or which justifications you might use. And this is a complex process, right, to compile the data, to analyze the data, to evaluate the data in the end. And this should be aligned with the risk analysis and finally the outcome of, the risk management process steps, including risk control, should be in the BR, and the outcome should also be aligned with other parts of the technical documentation if there are changes in the IFU, for example. So this is more critically. It takes also more time. We get more feedback, but, yeah, as of high expectations. These are regulatory insights. The focus is really going into chemical characterization. If they make a first formal check and there's no chemical characterization included, we immediately get it back. So they do require a chemical characterization, not necessarily by analysis, but at least the so called theoretical composition of profiling. So a chemical characterization based on available data, which you can also conduct a toxicological risk assessment on. So this is good, but, the the higher the associated biological risk, the more you need the analysis, right, and extractables or leachables profile. Especially in implants and devices in contact with circulating blood, the analysis is really required. And what leaches out or is extracted from the materials from the medical device and, yeah, this should go into a toxicological risk assessment. Because this chemical characterization went so dramatically into focus, we experienced a delay in lab availability and also in testing duration. So this should be really planned in advance. And there's also missing global harmonization. So in general, ISO 10,903 is very well acknowledged globally in Asia, even with the FDA in The UK, Canada. However, there's country specific guidance on the ISO ten ninety nine three series of SANADs, and this guidance didn't always catch up. So, we still need to check country specific if it is acknowledged or not, but most of the countries follow state of the art, and acknowledge ten nine nine three. And since this new revision is more going into the direction of... Yeah. It's stricter genotoxicity, for example, and also going more into direction of worst case considering the life cycle, foreseeable misuse, something like this bioaccumulation. It is stricter in this sense. It's also expected that it's rather acknowledged globally. Finally, our formal insights, yeah, it's mostly related on, experience and competency. So historically, research and development was often responsible for the documentation or for the biological evaluation. And r and d implies or is mostly consisted of engineers and material scientists. And we experience feedback from the notified body that they say there's often insufficiently demonstrated competence in, the form of education, training, skills, experience visible in the CV. And what is lacking is mostly experience in natural sciences, so research of literature, research in toxicological or chemical databases, something like this. So this is the opportunity to team up, to make some new friends, to get a coffee, and bring different people from different divisions on one table. Regulatory affairs, quality management, risk management, of course, included r and d because those are still the experts on the material and why this material is suitable for its intended purpose on the residues, how to manufacture this device. But also toxicology, natural science, of course, and clinical affairs. You could exploit or you can exploit, history of safe clinical use and support your biological evaluation. So invite them as well. This is... Yeah. It's really nice and also great to get insights from other divisions, work together on one aim. Yeah. Those were our experience. I'm looking forward what comes in the future. I think we are not there yet. I'm looking forward that these gaps are closed. There are some more, and this was... Will really help. Yeah. Let's start on the on the final section in my keynote today. This is the FDA expectations on biological evaluation. At the moment, we have still the FDA guidance on ISO ten nine three dash one. It corresponds to ISO ten nine three dash one from 2018. It was published in 2023. And what we, see... Saw in March... In May, excuse me, was the partial recognition of the new standard. This supersedes the previous, recognition of ISO ten ninety three dash one. However, it has a grace period for premarket submissions until July 2029. So I said it was partially recognized. There were two points which are not recognized. The first one is the phrase consumer products in clause six five something. This refers to a clause saying if there are medical devices in contact with intact skin and materials are well known and commonly used in consumer products, it is considered to be safe. That's good. However, the FDA has attachment g in their FDA guidance. And within attachment g, there's an entire list of materials considered by the FDA biologically safe based on their history of safe use in the past. And this... Yeah. Since there are two different strategies, simply how to evaluate commonly known materials in contact with intact skin, the FDA didn't acknowledge this consumer products part. This is reasonable. I understand. The second clause which they didn't recognize is clause six nine on biological risk estimation, and it's just described in conflict with ISO 14,971. So we went into the standard. We went into the ISO 14,971. We compared the text. We compared the process steps, and we didn't see any difference. So it was really a miracle why it was not accepted. We contacted one of the technical, committee members developing ISO 10,003 dash one, and he told us there's just insufficient implementation guidance. So there's insufficient guidance in ISO 10,003 dash one how to conduct the risk estimation on biological hazards. He said there will be a guidance in the future. And for the time being, we should refer to ISO forty nine seventy one and the FDA guidance, which is related, however, to the 2018 revision of, this... The ISO 10 and half three dash one. He also told us that the FDA does not intend to revise its biocompatibility guidance at this time. So we were... Oh, ah, this is surprising, because there is first and foremost different terminology. The simplest example is endpoints were renamed to biological effects. There are different biological effects to evaluate. For example, genotoxicity is more general. Material mediated pyrogenicity was a strong focus of the FDA in the past, so they always discuss material mediated pyrogenicity, and now it went out of the focus in the ISO. So we are not certain how to handle material mediated pyrogenicity and if the FDA would accept, the justification which is provided in the ISO. Right? And it has additional requirements, which are not included in the in the FDA guidance. So on the page, where you can see the recognized consensus standards and the description what is recognized, FDA states, we encourage you to contact the review offices, and this is what we also recommend from our experience in in the past year. So if you talk about intermittent contact, bioaccumulation, reasonably foreseeable misuse, or the medical device life cycle because you shouldn't only consider manufacturing a medical device. It's packed. It's sterilized. It's going into the market, maybe shelf life. But also what is beyond, remanufacturing, for example, aging. Yeah. Until disposal, whatever comes next, environment, biological environment, interactions, something like this, or these additional genotoxicity requirements in addition to pyrogenicity. So, yeah, a precept meeting is really recommended if you want to discuss your biological evaluation strategy. Yeah. And this... Yeah. This is comparison, basically, how we go with the ISO and how it's compared to the FDA practice. The ISO follows consequently a risk based approach with coherent argumentation. If notified by the reviewers see how your argumentation goes, the justification can be followed. It's reasonable. It's science based. It's common sense. They go with the risk based approach. It's really well accepted. And this leads to finally following just really our principle of replacement, reduction, and refinement of animal testing. So animal welfare is really, yeah, taking place right now with this risk based approach. Chemical characterization is primary source of safety data. If you don't have it, it's it's, yeah, it's coming back. And in vitro testing is preferred. We experience that, in vitro testing is even accepted if the testing is not necessarily validated according to ten ninety three. Yeah. You could suggest any new approach methodologies if it's applicable to your product, if you can justify the methods, and if the reviewer sees that it's really going to the outcome required for a biological evaluation and supporting the risk assessment. While the FDA, it's still a little bit more conservative. They acknowledge the risk based approach, but they still have a strong focus on sufficient evidence. So they don't accept data gaps even if they are insignificant on you state with justification why you are still able to conduct risk assessment. And the reviewers often still require the full set of testing for additional verification. Chemical characterization is also required. So it's similar like with, for example, European notified body. If there is no chemical characterization, it comes back. However, it still only supports the evidence. It's not primary source of safety data and in vivo is frequently expected. So following the three r principle is difficult if you go for, for example, EU and FDA. So consequently, you need a dual compliance strategy if you go for Europe and FDA. There is often over testing for FDA compliance. So if you don't need the testing in the EU, you just need it for the FDA. That's, yeah, that's really disadvantages, and it's unfortunate. And pre sub meetings are recommended. And this brings us to the scenario on the right side, which we faced repeatedly in the last year and even before. So that notified by the reviewers, since you need justification for the conduction of testing but also for weighting of testing, they ask, what is your rationale for this in vivo irritation testing? And the reply of the manufacturers is, yeah, we included US as a market of interest, and they don't accept in vitro if it's not validated or relying on available data or relying on the chemical characterization only. Yeah. Presub meetings are really recommended for specific topics, especially the new topics came with the new standard. And that is also one of my take home messages, and other ones are start early within the design process. Start with the first material, identified suitable for the intended purpose, and we should evaluate constantly during the life cycle along with the risk management. Right? We we should include all stakeholders from the beginning. I have much more meetings with, risk management with, well, I'm a scientist by myself, but with r and d, with, yeah, different people, suppliers, yeah, consulting in which testing did you perform, something like this. Yeah. And follow the... Or we should follow the iterative process, which is given by the risk based approach. First, exploit available data, literature research, toxicological data, put it into risk assessment, and only significant tests... Only significant data gaps should be filled with, testing. First, starting with in vitro and then going to in vivo. So in vivo testing in animal should be last resort unless you go for the FDA, unfortunately. Yeah. This is the end of the biological safety section. What we can do for you at NSF is basically everything, which is summarized in this slide. As soon as you have a question or a task related to biological safety or anything else, not only biological safety, just contact us. I give my contact information in the end of these slides. And there is a summit in Hamburg, which I really want to announce. It's a nice event, on November 12 here in Hamburg. It's a beautiful city. It's worth a visit. And we... So the beauty of this event is we bring together in the presentation tundams of, medical device manufacturers, so the industry with consultants from NSF. And in one presentation, focusing on one product or one process, we get the industry view and the practic... Yeah. Practical experience, something like this, along with the regulation and requirements, which are given in written form by our consultants. That's really great. I'm looking forward to it. And we have speakers from Olympus, Bebroun, Ipsumet, Karl Stodts, and Siemens. So these are really the big ones. They know what they talk about. I'm looking forward to it. Just check on this QR code, and I'm looking forward to meet you on this beautiful event in November in Hamburg. We have more webinars like this one today. It's free of charge, and learn about the regulatory world within less than an hour. Just check on this QR code. I did it today, and then there are really beautiful ones in there, exciting ones, about... So in October, QMSR, which was published by the FDA in February. And there's more information on QMSR and how it works in this keynote. But also quality management system according to thirteen four eighty five within October, and there are more in the end of this year and next year. So, yeah, check on this offer. This is really valuable. And what else does it need? If you have a question, contact us. Or if you don't have a question, just contact our website. There are nice white papers there. LinkedIn, you always get, yeah, ideas or we can just share experience. Call us if you have something on your mind. We are looking forward to get into contact with you. Yeah. And as promised, here is my contact information. You can also contact me directly, and I bring you together. If it's not about biological safety, clinical evaluation, or any clinical affairs, I bring you together on one table or in one call with one of my wonderful colleagues, which are really... Or who are really experts in the field. Thank you so much for attending today.